EcoDrugPlus

Cytochrome P450 3a27-Like

Ensembl ID : ENSAOCG00000007451
Gene Symbol: LOC111579976
2 Cross references
556 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSAOCG00000007469
Gene Symbol: LOC111579974
2 Cross references
551 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSAOCG00000009660
Gene Symbol: LOC111572716
2 Cross references
553 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSAOCG00000001757
Gene Symbol: LOC111586509
3 Cross references
494 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSAOCG00000015406
Gene Symbol: LOC111566926
3 Cross references
572 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSAOCG00000003386
Gene Symbol: CYP19A1
4 Cross references
246 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSAOCG00000016892
Gene Symbol: LOC111565186
2 Cross references
195 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSAOCG00000018631
Gene Symbol: LOC111565711
3 Cross references
178 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSAOCG00000023375
Gene Symbol: LOC111571496
3 Cross references
215 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSAOCG00000009107
Gene Symbol: LOC111579539
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSAOCG00000023266
Gene Symbol: LOC111567391
3 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSAOCG00000003933
Gene Symbol: LOC111573142
3 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).